DonCorleone77
Posted - 4 days ago
$ABOS Acumen sees cash runway into 1H27 Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027.
DonCorleone77
Posted - 4 days ago
$ABOS Acumen reports Q1 EPS (25c), consensus (26c) "In the first quarter, our team remained laser-focused on the initiation of ALTITUDE-AD, our Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD. We announced the first patient dosed in this study just last week. We are encouraged by the level of investigator interest in the potential of sabirnetug to offer a best-in-class therapeutic profile for patients, which is a testament to our strong Phase 1 data package and the relationships our team has built with clinical sites," Daniel O'Connell, Chief Executive Officer of Acumen. "We continue to expect to initiate a Phase 1 study with a subcutaneous form of sabirnetug in mid-2024 in an effort to extend the product profile and offer administration optionality for patients. We remain committed to delivering on our strategic priority to advance the clinical development of sabirnetug efficiently and thoughtfully."
Stock_Titan
Posted - 4 days ago
$ABOS Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-reports-first-quarter-2024-financial-results-u16vxl0kmomv.html
DonCorleone77
Posted - 1 week ago
$ABOS Acumen announces first patient dosed in ALTITUDE-AD study Acumen Pharmaceuticals announced that the first patient has been dosed with sabirnetug in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD. "Today marks a significant milestone for Acumen and the Alzheimer's community as we begin the Phase 2 trial of sabirnetug," said Daniel O'Connell, Chief Executive Officer of Acumen. "Sabirnetug is at the forefront of the next generation of Alzheimer's therapies, with encouraging Phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug's therapeutic potential and a strong start to the trial."
Stock_Titan
Posted - 1 week ago
$ABOS Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-announces-first-patient-dosed-in-altitude-ad-i7bin2y8e2a5.html
Stock_Titan
Posted - 1 week ago
$ABOS Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-to-report-first-quarter-results-on-may-14-mub2e9q3uqdj.html
Bigeyes2
Posted - 2 weeks ago
$ABOS swing
Lpd2111
Posted - 04/30/24
$ABOS $ATOS
🚀🌖
DonCorleone77
Posted - 1 month ago
$ABOS Acumen presents first clinical, biomarker data for ACU193 Acumen Pharmaceuticals will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug in early AD during an Emerging Science Session at the American Academy of Neurology 2024 Annual Meeting in Denver on April 16, 2024. The results build upon Acumen's prior presentations at the AD/PD 2024 Annual Meeting and positive topline data first announced in July 2023 and will be presented together for the first time with expanded analysis. "For the first time, we're presenting a comprehensive set of safety, biomarker and target engagement data from INTERCEPT-AD, which continue to support sabirnetug's mechanism and potential to offer differentiated safety and efficacy as a next-generation treatment for people with early Alzheimer's disease," said Eric Siemers, M.D., Chief Medical Officer of Acumen and presenting author. "The results of this robust Phase 1 trial give us hope that sabirnetug could have a safety and efficacy profile that could make it an attractive option for a large number of patients. We look forward to applying insights learned from INTERCEPT-AD as we embark upon our ALTITUDE-AD Phase 2 trial for sabirnetug."
Stock_Titan
Posted - 1 month ago
$ABOS Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-presents-first-comprehensive-clinical-and-3odnemo10q9h.html
NoFearHere
Posted - 1 month ago
$ABOS cracks me up for some reason this room in this stock is like a ghost town but something big is happening soon I think it pops upward not downward from this huge symmetrical triangle
NoFearHere
Posted - 1 month ago
$ABOS I'm glad I reviewed the stock this chart clearly shows something's about to happen I think it's upward SUPPORT = 3.70 +3.60 +300 RESIST = 4.05 + 4.33 = break out
commoncentsinvestor
Posted - 1 month ago
$ABOS SMALL CAP INVESTORS Anyone looking for a stock that could have a big increase in share price in 2024 might want to take a look at CVRX. They got FDA approval for its Barostim product to improve the lives of people suffering from heart failure back in 2019. They have spent the last 4 years building a market for their product and it is about to reap big rewards. They have been increasing their revenues, the number of implant centers, their territories, , and their public visibility by leaps and bounds and work on 84% gross margins. This should all result in big increases in revenues and share price this year. I expect a minimum of $65M in 2024 revenues and with 84% Gross Margins, a 15 times Market Cap would be very reasonable. That would put the share price at about $47. Current Share Price is under $18. With only 600 followers on Stock Twits, it is very early in the game for folks who like to invest in under followed small companies with HUGE potential.
TheTradeXchange
Posted - 1 month ago
$ABOS Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Stock_Titan
Posted - 1 month ago
$ABOS Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-collaborates-with-lonza-to-advance-sabirnetug-8s09sxlr5dsj.html
DonCorleone77
Posted - 03/31/24
$ABOS Acumen price target lowered to $14 from $15 at UBS UBS lowered the firm's price target on Acumen Pharmaceuticals to $14 from $15 and keeps a Buy rating on the shares. The analyst updated the company's model to include a reevaluation of the launch trajectory and probability of success for sabirnetug. Importantly, Acumen has sufficient cash to fund operations through the Phase 2 readout in early 2027, the analyst tells investors in a research note. The firm believes Acumen is now in a period of execution and sees an attractive buying opportunity at current valuation levels despite a "light catalyst path" in the near term.
G101SPM
Posted - 03/28/24
#DILUTION $ABOS files $200 mln mixed shelf securities offering. $PYXS files for 10,460,586 shares of common stock by selling shareholders. $FET files for 1,946,038 shares of common stock by selling shareholders. $LUNR files $300 mln common stock offering; also files for 159,808,031 shares of common stock by selling shareholders, relates to warrants
DonCorleone77
Posted - 03/27/24
$ABOS Acumen files $200M mixed securities shelf
Drerekcohert90
Posted - 03/27/24
$ABOS I got in yesterday based on your Telegram text at around 3.60 and exits today at 4.26. You are the man! You are on fire!
Bad_The_Bull_Bunny
Posted - 03/27/24
$ABOS slowly but moving in the right direction
jacksparo
Posted - 03/27/24
$ABOS What about that Telegram folks 😁😁😁😁
Bad_The_Bull_Bunny
Posted - 03/27/24
$ABOS looks heavy, waiting for a break
jacksparo
Posted - 03/27/24
$ABOS Getting back on track again!
ESanta
Posted - 03/26/24
$ABOS
mikesterz7
Posted - 03/26/24
$ABOS Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease expected in the first half of 2024
Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024
Cash, cash equivalents and marketable securities of $306.1 million as of Dec. 31, 2023, expected to support current clinical and operational activities into the first half of 2027
DonCorleone77
Posted - 03/26/24
$ABOS Acumen sees cash runway into 1H27 As of December 31, 2023, cash, cash equivalents and marketable securities totaled $306.1 million, compared to cash, cash equivalents and marketable securities of $193.4 million as of December 31, 2022. This increase is due to the net proceeds from the Company's public offering of approximately $122 million on July 21, 2023, as well as approximately $30 million from K2 HealthVentures as part of a debt financing of up to $50 million announced in November 2023. Altogether, this runway is now expected to be sufficient to support current clinical and operational activities into the first half of 2027.
DonCorleone77
Posted - 03/26/24
$ABOS Acumen reports 2023 EPS ($1.08), consensus ($1.07) "2023 was a landmark year for Acumen. We delivered the first Phase 1 results from an oligomer-targeted antibody for the treatment of early Alzheimer's disease, which exceeded expectations. Beyond favorable safety results, our study confirmed near-maximal target engagement of abeta oligomers, significant plaque reduction and impressive improvements in fluid biomarkers for AD that together give us increased confidence that sabirnetug may offer a best-in-class therapeutic profile for patients," said Daniel O'Connell, Chief Executive Officer of Acumen. "We have entered 2024 from a position of strength. Our team is laser-focused on advancing the clinical development of sabirnetug and expects to initiate our Phase 2 study in the first half of this year. We also expect to initiate a subcutaneous bioavailability study in mid-2024, to extend the product profile and offer administration optionality for patients...."
Stock_Titan
Posted - 03/26/24
$ABOS Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
https://www.stocktitan.net/news/ABOS/acumen-pharmaceuticals-reports-financial-results-for-the-year-ended-hnupqhfi9e2p.html
